Delgocitinib - Japan Tobacco

Drug Profile

Delgocitinib - Japan Tobacco

Alternative Names: JTE-052; JTE-052A; LEO 124249; LP0133

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; LEO Pharma
  • Class Antiallergics; Antipsoriatics; Pyrimidines; Skin disorder therapies
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata; Autoimmune disorders; Eczema; Hypersensitivity; Inverse psoriasis

Most Recent Events

  • 19 Mar 2018 Japan Tobacco signs license agreement with Rohto pharmaceutical for the development and commercialization of JTE 52 for Eye disorders in Japan
  • 15 Feb 2018 Japan Tobacco completes a phase II trial in Atopic dermatitis (In children, In adolescents) in Japan (Topical) (JapicCTI173553)
  • 30 Jan 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top